OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions
Protein OTUD7B plays complex roles in cancer and heart health
This systematic review examines the molecular roles of OTUD7B across multiple malignancies and inflammatory models. The findings indicate th…
A protein called OTUD7B acts as a double-edged sword, helping some conditions while fueling the growth of others.
Attenuated R-THP-COP regimen achieved complete response in an 85-year-old with diffuse large B-cell lymphoma
Attenuated R-THP-COP regimen shows promise for elderly diffuse large B-cell lymphoma
This case report describes an 85-year-old female patient with diffuse large B-cell lymphoma treated with an attenuated R-THP-COP regimen. Th…
An 85-year-old woman achieved complete radiological response and remained symptom-free for three years on an attenuated chemotherapy regimen…
Zanubrutinib Delivers High Response Rates And Survival Benefits Across Diffuse Large B-Cell Lymphoma Patient Groups In This Meta-Analysis
Zanubrutinib shows high response rates in diffuse large B-cell lymphoma patients
A meta-analysis of 1,346 patients with diffuse large B-cell lymphoma shows zanubrutinib achieves high response rates and prolonged survival.…
Zanubrutinib helped 95 out of 100 previously untreated patients with diffuse large B-cell lymphoma respond to treatment in this analysis.
Immunotherapies beyond rituximab show high response rates in diffuse large B-cell lymphoma
New immunotherapy options offer high response rates for Diffuse Large B-Cell Lymphoma patients
This narrative review surveys immunotherapy options for diffuse large B-cell lymphoma beyond rituximab, including bispecific antibodies, CAR…
New immunotherapy treatments show high response rates for Diffuse Large B-Cell Lymphoma, offering hope beyond the standard 60% success rate …
Meta-analysis of double-expressor lymphoma prognoses and novel therapies
Double-expressor lymphoma linked to worse survival outcomes in large study
This systematic evaluation meta-analysis of 9,808 patients with diffuse large B-cell lymphoma found double-expressor lymphoma (DEL) is assoc…
A major review finds double-expressor lymphoma patients have worse survival. New drug combinations show promise for better results.
Tucidinostat plus R-CHOP improves outcomes in MYC/BCL2 double-expressor DLBCL
New drug tucidinostat improves outcomes for high-risk lymphoma patients
A phase 3 trial found adding oral tucidinostat to R-CHOP significantly improved event-free survival and complete response rates in patients …
A large trial shows adding tucidinostat to standard chemo lowers disease risk and improves survival for patients with aggressive lymphoma.
FDA Approves Xpovio (selinexor) for Multiple Myeloma and DLBCL
FDA approves new drug Xpovio for certain blood cancers.
The FDA approved Xpovio (selinexor) for multiple myeloma in combination with bortezomib and dexamethasone after at least one prior therapy, …
The FDA approved Xpovio (selinexor) for multiple myeloma and a type of lymphoma called DLBCL. It offers a new option for patients who have t…
Experimental agents show response rates up to 70% in relapsed or refractory diffuse large B-cell lymphoma
New cancer therapies double response rates for tough lymphoma
This systematic review and meta-analysis of phase 1-2 trials evaluated experimental agents alone or combined with CD20-antibodies in adults …
Patients with aggressive lymphoma once had few options after standard treatments failed, but new therapies are changing that outlook in ways…
Mecapegfilgrastim reduces grade 3+ neutropenia in treatment-naive diffuse large B-cell lymphoma patients versus no prophylaxis
New Drug Cuts Severe Infection Risk In Lymphoma Care
This randomized controlled trial evaluated mecapegfilgrastim in 42 treatment-naive patients with diffuse large B-cell lymphoma.
A new long-acting injection lowers the risk of dangerous low white blood cell counts in lymphoma patients starting their first round of chem…
Case report documents HIV-associated diffuse large B-cell lymphoma regression with cART
1. HEADLINE
This case report and literature review describes a 66-year-old male with stage IV HIV-associated diffuse large B-cell lymphoma.
HIV Treatment Clears Advanced Lymphoma Without Chemo
Eight-gene signature associated with survival in patients with Diffuse Large B-cell lymphoma
Doctors find a new way to predict who needs stronger cancer care sooner
In this cohort study, a predictive signature based on the reactivation of eight normally silent tissue-dependent genes was identified in pat…
A new blood test can spot dangerous lymphoma risks early so doctors can change treatment plans before patients get sicker.
Tisagenlecleucel in Korean patients with relapsed or refractory diffuse large B-cell lymphoma
New Lymphoma Therapy Helps Patients Live Longer
This retrospective cohort study of 79 Korean patients with relapsed or refractory diffuse large B-cell lymphoma evaluated tisagenlecleucel.
A new study shows a specific immune therapy can shrink tumors and extend life for lymphoma patients who have run out of options.
Research across Non-Hodgkin's Lymphoma
Related studies from across the Non-Hodgkin's Lymphoma family.
Ibrutinib plus chemo without ASCT shows survival benefit in mantle cell lymphoma
Adding stem cell transplant to ibrutinib treatment offered no extra benefit for lymphoma patients
In younger patients with mantle cell lymphoma, adding ASCT to an ibrutinib regimen did not improve outcomes but increased toxicity. Ibrutini…
Adding stem cell transplant to ibrutinib did not improve survival for younger lymphoma patients but increased side effects.
Systematic landscape analysis of CAR-T trials for non-Hodgkin lymphoma finds early-phase focus
CAR-T Trials Show Promise But Face Big Hurdles For Lymphoma Patients
This systematic landscape review of 360 CAR-T cell therapy trials for non-Hodgkin lymphoma found rapid expansion with a predominant focus on…
New research shows that CAR-T cell trials are expanding quickly but scientists must solve big problems like drug resistance before patients …
FDA Approves Revlimid (lenalidomide) for Multiple Myeloma and Other Indications
FDA approves Revlimid for several blood cancers and related conditions.
FDA approved Revlimid (lenalidomide) for multiple myeloma (in combination with dexamethasone and as maintenance after auto-HSCT), transfusio…
The FDA approved Revlimid (lenalidomide) for multiple myeloma, certain myelodysplastic syndromes, mantle cell lymphoma, and other lymphomas.…
Fixed-duration subcutaneous mosunetuzumab shows favorable efficacy and safety versus IV in relapsed follicular lymphoma
Subcutaneous Mosunetuzumab Shows Promise for Follicular Lymphoma Patients
This Phase 2 primary analysis evaluated fixed-duration subcutaneous mosunetuzumab versus mosunetuzumab IV in patients with relapsed or refra…
A Phase 2 trial found subcutaneous mosunetuzumab had lower rates of severe side effects than the IV version for treating follicular lymphoma…
Abexinostat showed a 69.5% objective response rate in relapsed follicular lymphoma patients
New Drug Shrinks Stubborn Lymphoma Tumors After Other Treatments Fail
This single-arm, multi-center phase 2 study evaluated abexinostat in 90 patients with relapsed or refractory follicular lymphoma who had rec…
A new treatment is helping some patients with stubborn lymphoma shrink tumors and stay in control for over a year, even after other therapie…
Review of case report discusses anti-PL-12 antisynthetase syndrome and NK/T-cell non-Hodgkin lymphoma
Patient with anti-PL-12 syndrome and lymphoma: a rare case report
This review of a case report describes a patient with anti-PL-12 antisynthetase syndrome and NK/T-cell non-Hodgkin lymphoma.
A single patient with anti-PL-12 antisynthetase syndrome and NK/T-cell lymphoma highlights the need for caution when interpreting rare cance…
Narrative review explores strategies to prevent CAR-T cell exhaustion in treatment-resistant non-Hodgkin lymphoma
New Strategies to Keep CAR-T Cells Strong Against Cancer
This narrative review examines strategies to prevent CAR-T cell exhaustion in patients with treatment-resistant non-Hodgkin lymphoma.
This review explains how to stop immune cells from giving up on fighting cancer.
Meta-analysis of novel therapies for follicular lymphoma progression within 24 months shows high response rates
New treatments show high response rates for advanced follicular lymphoma patients
This systematic review and meta-analysis evaluated outcomes for patients with follicular lymphoma experiencing disease progression within 24…
New powerful medicines help 91% of advanced follicular lymphoma patients whose disease returned quickly after treatment.
Mitoxantrone liposome plus CMOP shows high response rates in untreated peripheral T-cell lymphoma patients
New Drug Combo Helps Most Patients With Hard-to-Treat Lymphoma
This phase 1b multicenter clinical trial evaluated mitoxantrone hydrochloride liposome combined with cyclophosphamide, vincristine, and pred…
A new drug combo wrapped in fat bubbles helped 89% of patients with hard-to-treat lymphoma shrink tumors without causing deaths.
Systematic review finds highest glyphosate exposure associated with increased NHL risk
Higher glyphosate herbicide exposure linked to increased lymphoma risk in research review
A systematic review and meta-analysis of 20 observational study populations found that ever exposure to glyphosate-based herbicides was not …
People with the highest glyphosate herbicide exposure had about a 38% higher chance of developing non-Hodgkin's lymphoma compared to those w…
R-CVP after radiotherapy improves progression-free survival in early-stage follicular lymphoma
Can adding a drug cocktail to radiation help keep early lymphoma from returning?
In a multicenter RCT with 150 patients with early-stage follicular lymphoma and 11.3-year median follow-up, involved-field radiotherapy plus…
Adding R-CVP drugs to radiation therapy helps early-stage lymphoma patients stay cancer-free longer, with mostly temporary side effects and …
Case report describes management of Burkitt's lymphoma with concurrent HIV, CMV encephalitis, and salmonella bacteremia
Case report describes complex treatment for man with lymphoma, HIV, and infections
A case report describes a 50-year-old man with newly diagnosed HIV, stage IV Burkitt's lymphoma with CNS and marrow involvement, CMV viremia…
Doctors managed a 50-year-old man with newly diagnosed HIV, aggressive lymphoma, and multiple serious infections through coordinated care fr…
All Diffuse Large B-Cell Lymphoma Articles
- OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions
- Attenuated R-THP-COP regimen achieved complete response in an 85-year-old with diffuse large B-cell lymphoma
- Zanubrutinib Delivers High Response Rates And Survival Benefits Across Diffuse Large B-Cell Lymphoma Patient Groups In This Meta-Analysis
- Immunotherapies beyond rituximab show high response rates in diffuse large B-cell lymphoma
- Meta-analysis of double-expressor lymphoma prognoses and novel therapies
- Tucidinostat plus R-CHOP improves outcomes in MYC/BCL2 double-expressor DLBCL
- FDA Approves Xpovio (selinexor) for Multiple Myeloma and DLBCL
- Experimental agents show response rates up to 70% in relapsed or refractory diffuse large B-cell lymphoma
- Mecapegfilgrastim reduces grade 3+ neutropenia in treatment-naive diffuse large B-cell lymphoma patients versus no prophylaxis
- Case report documents HIV-associated diffuse large B-cell lymphoma regression with cART
- Eight-gene signature associated with survival in patients with Diffuse Large B-cell lymphoma
- Tisagenlecleucel in Korean patients with relapsed or refractory diffuse large B-cell lymphoma
- High FGR protein expression associated with worse relapse-free survival in de novo DLBCL patients treated with R-CHOP
- High-dose pegylated liposomal doxorubicin shows comparable survival to conventional doxorubicin in DLBCL with reduced toxicity
- CD5-positive DLBCL diagnosed in a 74-year-old woman via uterine drainage fluid analysis
- Phase 2 trial compares Inotuzumab Ozogamicin plus R-CVP for DLBCL patients unfit for anthracycline
- Case report describes treatment response in rare dual-lesion DLBCL with heterogeneous subtypes